BSECompany Update2d ago · 27 Oct 2026, 08:21 pm
Investor''s presentation on unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026
Concord Biotech Ltd · 543960
✦ AI Summary▲ PositiveResults
Concord Biotech Ltd has announced its unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026, showing a broad-based growth across all product categories and geographies, with a 26% increase in revenue and 25% increase in EBITDA.
Analysis Scores
Earnings Impact8/10
Growth Catalyst7/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact9/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor Presentation